Famotidine Use Is Not Associated With 30-day Mortality: A Coarsened Exact Match Study in 7158 Hospitalized Patients With Coronavirus Disease 2019 From a Large Healthcare System
Samrat Yeramaneni, Pratik Doshi, Kenneth Sands, Mandelin Cooper, Dax Kurbegov, Gregg Fromell
Gastroenterology, doi:10.1053/j.gastro.2020.10.011
P revious reports have found that in-hospital famotidine use in coronavirus disease 2019 (COVID-19) patients was associated with reduced risk of death or intubation. 1, 2 In 1 of these studies the authors proposed that famotidine inhibits the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protease, 3-chymotrypsin-like protease, that is essential for breakdown of the immature SARS-CoV-2 protein particles that contribute to the inflammatory response seen in some COVID-19-infected individuals, 1 which in turn can lead to acute respiratory distress syndrome, multiorgan dysfunction, physiologic deterioration, and death. 3 In a global pandemic with a lack of US Food and Drug Administration-approved targeted therapeutic agents, identification and repurposing of well-established drugs with a proven track record of safety, affordability, and widespread availability are necessary. 4 The purpose of this study was to evaluate the reported protective effect of famotidine on mortality in hospitalized COVID-19 patients.
Supplementary Material Note: To access the supplementary material accompanying this article, visit the online version of Gastroenterology at www.gastrojournal.org and at https://doi.org/10.1053/ j.gastro.2020.10.011.
Conflicts of interest The authors disclose no conflicts.
References
Dr, Luther, Boulevard, Suite 800
Freedberg, None, Gastroenterology
Iacus, None, Political Analysis
Mather, None, Am J Gastroenterol
Rogosnitzky, None, JMIR Public Health Surveill
Wang, None, Lancet
Zhou, None, Lancet